Work

Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy

Year: 2012
Type: review
Abstract: Advances in cancer therapy, early detection, and supportive care have contributed to steady gains in the 5-year relative survival rate for all cancers combined, which reached 66.0% for patients diagnosed during 1999-2006 (1).Commensurately, the number of cancer survivors in the United States has tripled since 1971 and is growing by 2% each year.As of 2007, there were approximately 12 million men and women in the United States-approximately 3.5% of the US population-with a history of cancer (1).For many patients, these gains in survival have come at the price of serious treatment-associated late adverse effects.Radiation remains a cornerstone of successful cancer treatment, with 50% of all patients estimated to receive radiotherapy (2).Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are two of the most frequent and important life-threatening adverse events associated with radiotherapy.Multiple primary cancers now account for approximately one in six of all incident cancers reported to the US Surveillance, Epidemiology, and End Results Program cancer registry (1).For patients with Hodgkin lymphoma (3), testicular cancer (4,5), and certain childhood cancers (6), SMNs have emerged as an important cause of death (7).Radiotherapy-associated CVD refers to a wide spectrum of disorders and is an important cause of morbidity and mortality, most notably after thoracic radiotherapy for Hodgkin lymphoma and tangential radiotherapy for breast cancer (8,9).With the increased awareness of the adverse consequences of cancer therapy, it has become critically important to identify measures to mitigate and ameliorate these late adverse effects and to provide cancer survivors with counseling, surveillance, and supportive care.In addition, it is essential to review and balance the risks and benefits of new treatment options as they become available.Providing a research infrastructure for transdisciplinary studies of cancer survivors is also important (10).The Childhood Cancer Survivorship Study (CCSS) is a critical resource for outcome and intervention research in survivors of pediatric and adolescent cancer (11); however, a comparable research base is lacking for survivors of young adult-onset (12,13) and other cancers.The expanding use of radiotherapy and development of new radiation modalities to treat cancer, coupled with improvements in longterm patient survival, underscores the importance of continuing to provide long-term risk estimates as well as additional research into the molecular underpinnings of treatment-related SMNs and CVD.Moreover, optimal screening and interventional efforts for these late adverse events must be identified (5).To review and address the expanding burden of late adverse effects after treatment with radiation, the National Council on
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2147498149
FWCI: 2.965
Cites: 209
Cited by: 236
Related to: 10